8 withdrawn. 8 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Withdrawn 8 |
| Phase 2 | 4 | Withdrawn 4 |
Follow Bendamustine: new trials by email Literature Review of Bendamustine trials Research Report on Bendamustine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer Bendamustine, Biopsy, Biospecimen Collection - Prostate Carcinoma, Prostate Small Cell Neuroendocrine Carcinoma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2025-04-15 | 2025-04-01 | |
| FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma FT596, Cyclophosphamide, Doxorubicin - Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hodgkin's Lymphoma | Phase 1 | Withdrawn | Fate Therapeutics | 2022-12-01 | 2023-07-06 | |
| Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma CC-220, Polatuzumab vedotin, Rituximab - Lymphoma, B-Cell | Phase 1 / Phase 2 | Withdrawn | Celgene | 2021-10-10 | 2021-10-05 | |
| Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) Selinexor, Rituximab, Bendamustine - Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Withdrawn | Karyopharm Therapeutics Inc | 2020-11-18 | 2025-10-03 | |
| Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL) ROR1R-CAR-T Cell Infusion, Fludarabine, Cyclophosphamide - Leukemia | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2015-01-01 | 2017-06-12 | |
| Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma Bendamustine - Multiple Myeloma, Plasma Cell Leukemia | Phase 1 | Withdrawn | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2014-06-01 | 2025-10-15 | |
| Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma bendamustine hydrochloride, obatoclax mesylate, rituximab - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2010-10-01 | 2013-06-06 | |
| Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL) Temsirolimus, Bendamustine - Mantle Cell Lymphoma | Phase 1 / Phase 2 | Withdrawn | Charite University, Berlin, Germany | 20 | 2010-05-01 | 2011-03-16 |
Lymphoma, Mantle-Cell (3) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Follicular (2) · Lymphoma, Large B-Cell, Diffuse (2) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Plasma Cell (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Prostatic Neoplasms (1) · Recurrence (1)
Celgene (1) · Charite University, Berlin, Germany (1) · Fate Therapeutics (1) · Fred Hutchinson Cancer Center (1) · Karyopharm Therapeutics Inc (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1)
United States (5) · Austria (1) · Belgium (1) · France (1) · Germany (1) · South Korea (1) · Spain (1) · Taiwan (1) · United Kingdom (1)
Christian Scholz, PD Dr. (1) · Elizabeth Christian (1) · Manish Sharma, MD (1) · Michael Schweizer (1) · William G. Wierda, MD, PHD, BS (1)
U01CA076576 (1)